Bausch Health Cos Sees Unusually High Options Volume (NYSE:BHC)

Bausch Health Cos Inc. (NYSE:BHC) was the recipient of unusually large options trading on Thursday. Stock investors purchased 4,021 call options on the stock. This is an increase of 134% compared to the average daily volume of 1,722 call options.

Bausch Health Cos Price Performance

BHC stock traded up $1.29 on Thursday, reaching $5.97. The company had a trading volume of 13,090,327 shares, compared to its average volume of 2,186,907. The company’s fifty day moving average is $4.95 and its 200 day moving average is $5.47. The company has a market cap of $2.23 billion, a P/E ratio of -1.84 and a beta of 0.42. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32. Bausch Health Cos has a 1 year low of $4.33 and a 1 year high of $8.69.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.30. Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The company had revenue of $2.83 billion during the quarter, compared to the consensus estimate of $2.59 billion. On average, research analysts forecast that Bausch Health Cos will post 4.05 earnings per share for the current year.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, Director Frank D. Lee sold 24,456 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total transaction of $132,796.08. Following the sale, the director directly owned 49,339 shares in the company, valued at approximately $267,910.77. The trade was a 33.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Institutional Trading of Bausch Health Cos

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Caption Management LLC lifted its holdings in Bausch Health Cos by 101.1% in the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after purchasing an additional 405,789 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Bausch Health Cos by 12,589.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after buying an additional 4,910 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of Bausch Health Cos by 6,661.2% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after buying an additional 5,329 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after buying an additional 3,106 shares during the last quarter. Finally, Camelot Portfolios LLC purchased a new position in shares of Bausch Health Cos during the fourth quarter valued at approximately $59,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Cos News Summary

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Second-quarter results beat expectations. Bausch Health reported adjusted earnings of $1.26 per share, versus the $0.96 analyst consensus, while revenue reached approximately $2.83 billion to $2.85 billion, above estimates near $2.59 billion. Adjusted EPS rose 40% year over year from $0.90, and adjusted EBITDA increased 28% to $1.075 billion. Bausch Health Q2 earnings and revenues beat estimates
• Positive Sentiment: Growth and cash flow supported the bullish reaction. Consolidated revenue increased 13% on a reported basis and 11% organically, marking the company’s thirteenth consecutive quarter of year-over-year revenue growth. Bausch Health also generated $517 million in operating cash flow and $471 million in adjusted cash flow from operations. Bausch Health announces second-quarter 2026 results and raises guidance
• Positive Sentiment: Full-year guidance was raised. Management now expects 2026 revenue of $10.8 billion to $11.0 billion, above the roughly $10.7 billion consensus estimate, and also raised its adjusted EBITDA and adjusted cash-flow guidance. Guidance update
• Positive Sentiment: Options activity signaled increased bullish interest. Traders purchased 4,021 BHC call options, 134% above the average volume of 1,722 contracts, potentially adding momentum to the stock.
• Negative Sentiment: Analysts at Zacks expect weaker earnings. The cautious earnings outlook could limit the rally if future results or guidance fail to sustain the latest beat. Zacks expects weaker earnings
• Negative Sentiment: Financial risks remain material. Bausch Health continues to report a negative net margin and carries substantial leverage, which may keep investors focused on debt reduction and the durability of its cash flow.

Wall Street Analyst Weigh In

BHC has been the subject of a number of research analyst reports. Weiss Ratings cut Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Royal Bank Of Canada lowered their price objective on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th. Jefferies Financial Group upgraded shares of Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd. Finally, Zacks Research cut shares of Bausch Health Cos from a “hold” rating to a “strong sell” rating in a research report on Friday, July 24th. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Bausch Health Cos has a consensus rating of “Reduce” and an average target price of $8.00.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.